» Articles » PMID: 10368301

Crystal Structure of the Kinase Domain of Human Vascular Endothelial Growth Factor Receptor 2: a Key Enzyme in Angiogenesis

Overview
Journal Structure
Publisher Cell Press
Date 1999 Jun 16
PMID 10368301
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Angiogenesis is involved in tumor growth, macular degeneration, retinopathy and other diseases. Vascular endothelial growth factor (VEGF) stimulates angiogenesis by binding to specific receptors (VEGFRs) on the surface of vascular endothelial cells. VEGFRs are receptor tyrosine kinases that, like the platelet-derived growth factor receptors (PDGFRs), contain a large insert within the kinase domain.

Results: We report here the generation, kinetic characterization, and 2.4 A crystal structure of the catalytic kinase domain of VEGF receptor 2 (VEGFR2). This protein construct, which lacks 50 central residues of the 68-residue kinase insert domain (KID), has comparable kinase activity to constructs containing the entire KID. The crystal structure, determined in an unliganded phosphorylated state, reveals an overall fold and catalytic residue positions similar to those observed in other tyrosine-kinase structures. The kinase activation loop, autophosphorylated on Y1059 prior to crystallization, is mostly disordered; however, a portion of it occupies a position inhibitory to substrate binding. The ends of the KID form a beta-like structure, not observed in other known tyrosine kinase structures, that packs near to the kinase C terminus.

Conclusions: The majority of the VEGFR2 KID residues are not necessary for kinase activity. The unique structure observed for the ends of the KID may also occur in other PDGFR family members and may serve to properly orient the KID for signal transduction. This VEGFR2 kinase structure provides a target for design of selective anti-angiogenic therapeutic agents.

Citing Articles

Discovery of novel VEGFR2 inhibitors against non-small cell lung cancer based on fingerprint-enhanced graph attention convolutional network.

Wang Z, Sun L, Xu Y, Huang J, Yang F, Chang Y J Transl Med. 2024; 22(1):1097.

PMID: 39627783 PMC: 11613592. DOI: 10.1186/s12967-024-05893-2.


Novel curcumin-based analogues as potential VEGFR2 inhibitors with promising metallic loading nanoparticles: synthesis, biological evaluation, and molecular modelling investigation.

Yassen A, Abdel-Wahab S, Darwish K, Nafie M, Abdelhameed R, El-Sayyad G RSC Med Chem. 2024; .

PMID: 39345715 PMC: 11428034. DOI: 10.1039/d4md00574k.


New BDNF and NT-3 Cyclic Mimetics Concur with Copper to Activate Trophic Signaling Pathways as Potential Molecular Entities to Protect Old Brains from Neurodegeneration.

Magri A, Tomasello B, Naletova I, Tabbi G, Cairns W, Greco V Biomolecules. 2024; 14(9).

PMID: 39334869 PMC: 11430436. DOI: 10.3390/biom14091104.


Deciphering the Genetic Complexity of Classical Hodgkin Lymphoma: Insights and Effective Strategies.

Lee C, An Y Curr Genomics. 2024; 25(5):334-342.

PMID: 39323623 PMC: 11420564. DOI: 10.2174/0113892029301904240513045755.


3D physiologically-informed deep learning for drug discovery of a novel vascular endothelial growth factor receptor-2 (VEGFR2).

Xu M, Xiao X, Chen Y, Zhou X, Parisi L, Ma R Heliyon. 2024; 10(16):e35769.

PMID: 39220924 PMC: 11365333. DOI: 10.1016/j.heliyon.2024.e35769.